Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives

Discussions underway to expand adoption of ChemoFx in the U.S. and accelerate initial launch in Europe

Read more at globenewswire.com